Literature DB >> 27001118

Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.

Y C Yang1, G C Wu1, L Jin1, K L Wang1, Z G Bai1, J Wang1, Z T Zhang1.   

Abstract

Preoperative chemoradiotherapy (pCRT) followed by surgery is currently the standard therapy for patients with locally advanced rectal cancer. It is very important to develop biomarkers to prior identify the patients who have a higher likelihood of responding to pCRT. Recently, a series of studies have been conducted to investigate the association of thymidylate synthase (TYMS) polymorphisms with the tumor response to pCRT in rectal cancer, but the results were not consistent and conclusive. In the present study, we performed a systematic literature search for relevant studies up to 30 March 2015 and conducted a meta-analysis to summarize and clarify the association between the TYMS polymorphisms and the tumor response to pCRT in rectal cancer. Finally, 7 studies containing 892 cases for TYMS 2R/3R polymorphism, 7 studies involving 715 cases for TYMS 1494del6 polymorphism and 6 studies containing 616 cases for TYMS 5' untranslated region (UTR) expression allele polymorphism were analyzed in the meta-analysis. The results suggested that TYMS 2R/3R was associated with the response and the patients with 2R/2R or 2R/3R genotype with rectal cancer might benefit more from pCRT than others. On the contrary, neither 1494del6 nor 5'UTR expression allele polymorphisms was associated with the response to pCRT.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27001118     DOI: 10.1038/tpj.2016.11

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  36 in total

1.  EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Authors:  Siwen Hu-Lieskovan; Daniel Vallbohmer; Wu Zhang; Dongyun Yang; Alexander Pohl; Melissa J Labonte; Peter P Grimminger; Arnulf H Hölscher; Robert Semrau; Dirk Arnold; Kathrin Dellas; Annelies Debucquoy; Karin Haustermans; Jean-Pascal H Machiels; Christine Sempoux; Claus Rödel; Matej Bracko; Vaneja Velenik; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

2.  A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.

Authors:  Salvatore Terrazzino; Marco Agostini; Salvatore Pucciarelli; Lara Maria Pasetto; Maria Luisa Friso; Alessandro Ambrosi; Veronica Lisi; Alberta Leon; Mario Lise; Donato Nitti
Journal:  Pharmacogenet Genomics       Date:  2006-11       Impact factor: 2.089

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

5.  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Robert W Beart; Timothy F Wozniak; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini Soori; Janice F Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Saima Sharif; Mark S Roh; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2015-09-14       Impact factor: 13.506

6.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.

Authors:  Karen-Lise G Spindler; Jens N Nielsen; Jan Lindebjerg; Anders Jakobsen
Journal:  Dis Colon Rectum       Date:  2007-09       Impact factor: 4.585

8.  Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.

Authors:  Jan Stoehlmacher; Eray Goekkurt; Ulrike Mogck; Daniela E Aust; Michael Kramer; Gustavo B Baretton; Torsten Liersch; Gerhard Ehninger; Christiane Jakob
Journal:  Cancer Lett       Date:  2008-08-21       Impact factor: 8.679

9.  Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.

Authors:  David Páez; Laia Paré; Albert Altés; Francesc Josep Sancho-Poch; Lourdes Petriz; Jordi Garriga; Josep Maria Monill; Juliana Salazar; Elisabeth del Rio; Agustí Barnadas; Eugenio Marcuello; Montserrat Baiget
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-18       Impact factor: 4.553

10.  Capecitabine in the management of colorectal cancer.

Authors:  Bradford R Hirsch; S Yousuf Zafar
Journal:  Cancer Manag Res       Date:  2011-03-24       Impact factor: 3.989

View more
  1 in total

1.  Screening and identification of key biomarkers in adrenocortical carcinoma based on bioinformatics analysis.

Authors:  Zengmiao Xing; Zuojie Luo; Haiyan Yang; Zhenxing Huang; Xinghuan Liang
Journal:  Oncol Lett       Date:  2019-09-06       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.